Animal Testing has long been a hot topic in terms of requirements and acceptability. Recent changes in regulations mean it is more important, now than ever to find alternative methods that reduce or eliminate the need for animal testing in ensuring medicines and cosmetics are safe for humans. This is the second webinar in a series on Successful Alternatives to Animal Testing. In this webinar, the FDA’s biostatistician will review the use of Artificial Intelligence for Successful Alternatives to Animal Testing.
  • AI is NOT all about outcome prediction such as QSARs! - AI can also generate new data for biomarker development and mechanistic study!
  • We have developed a GAN framework to learn from existing animal data to produce new animal data without using animals. - AnimalGAN for clinical pathology measurements - ToxGAN for toxicogenomics data - Both AnimalGAN and ToxGAN are virtual animal models
  • Read-Across GAN (RAGAN) advances 3Rs and risk assessment: - Able to incorporate diverse biological data into read-across framework
Dr. Weida Tong
Director, Division of Bioinformatics and Biostatistics, FDA’s National Center for Toxicological Research (NCTR)
Dr. Weida Tong is Director of the Division of Bioinformatics and Biostatistics at the FDA’s National Center for Toxicological Research (NCTR). He has been an FDA Senior Biomedical Research and Biomedical Product Assessment Service expert since 2011, an Arkansas Research Alliance fellow since 2016, and a member of the Arkansas Academy of Computing since 2021. He has served on science advisory boards for several multi-institutional projects in Europe and the U.S. and also holds adjunct appointments at several universities. His primary research interests are in the fields of bioinformatics, artificial intelligence (AI), molecular modeling and data analytics for biomarker discovery, drug safety and repurposing, pharmacogenomics/toxicogenomics, and precision medicine. Currently, he directs several FDA mission-critical projects in his division. Dr. Tong has published over 300 peer-reviewed papers and book chapters.
Dr. Hongbao Cao
Senior Product Manager for Elsevier Biology Solutions
Dr. Hongbao Cao is a Senior Product Manager for Elsevier Biology Solutions based in Washington DC, USA. In his current role, Dr. Cao is focused on understanding the ongoing challenges of researchers in the field of biology, with the overall aim of developing information solutions that help them effectively innovate. One of the major projects Dr. Cao is currently working on is the in-silico biology (ISB) project that is based on the Elsevier Biology Knowledge database (EBKD). Dr. Cao earned his Biomedical Engineering (BME) Bachelor's and Master's degrees from Tianjin University, Tianjin, China, and his BME Ph.D. degree at Louisiana Tech University, USA. Before joining Elsevier, Dr. Cao worked at National Institute of Mental Health/National Institute of Health (NIMH/NIH) as a Senior Scientist. During the past years, Dr. Cao has done many research works in the field of disease modeling and bioinformatics with over 90 publications in peer-reviewed, high-quality journals.
Olivier Barberan
Director, Translational Medicine Solutions , Elsevier
Olivier Barberan is currently Director of Translational Medicine Solutions at Elsevier with more than 20 years of experience in the pharmaceutical industry and 15 years in product development leading to more than 40 peer review articles and short communications. He was previously Senior Product Manager of Reaxys Medicinal Chemistry at Elsevier. Following an Engineer degree in Chemistry at Ecole Centrale Marseille in 1996 and a PhD in Therapeutic Chemistry related to VEGF involvement in diabetic retinopathy at the University of Paris in 2000, he joined Aureus Sciences and held Project Manager positions for several fields including Kinase, GPCR, ADME/DDI. In 2006, he was appointed to a Director of Product Development position. After the acquisition of Aureus Sciences in 2013 by Elsevier, he moved into a new position in Elsevier Life Science group as Senior Product Manager of Reaxys Medicinal chemistry. In 2017, he was appointed as Director of translational medicine and responsible of the development of Pharmapendium as well as a new version a predictive tool for drug interactions involving cytochromes and UGTs based on in vitro in vivo extrapolation. 
Michelle Mohsenin RPh
Product Manager, Embase
Michelle Mohsenin Rph is a Product Manager for Elsevier supporting the biomedical journal database, Embase as a Drug Safety/Pharmacovigilance Subject Matter Expert. Prior to Elsevier she was Senior Drug Safety Officer for Pfizer where she led the Global Literature Surveillance group. She was responsible for being regulation compliance to ensure inspection readiness.  She is a licensed New Jersey pharmacist.

Register To Watch Recording
Full name*
Email Address*
Job Title*
Which gender do you most identify with
Marketing Permission
Elsevier (https://www.elsevier.com/about/locations) may send you information about relevant products and events. If you do NOT wish to receive such messages please check the box below For more information, please read our privacy policy.
I do not wish to receive marketing emails